Horizon Pharma plc to Acquire Worldwide Rights to

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Horizon Pharma plc to Acquire Worldwide Rights to Interferon Gamma-1b From Boehringer Ingelheim International GmbH

DUBLIN, IRELAND--(Marketwired - May 19, 2016) - Horizon Pharma plc ( NASDAQ : HZNP ) ("Horizon Pharma"), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that its affiliate has entered into a definitive agreement with Boehringer Ingelheim International GmbH ("Boehringer Ingelheim") to acquire the rights to interferon gamma-1b, which Boehringer Ingelheim commercializes under the trade names IMUKIN ® , IMUKINE ® , IMMUKIN ® and IMMUKINE® in an estimated 30 countries primarily in Europe and the Middle East.

"Obtaining worldwide rights for interferon gamma-1b solidifies our continued investment in the medicine, and pending the outcome of clinical studies investigating it in Friedreich's ataxia and advanced solid tumors, such as kidney and bladder cancer, strengthens our ability to expand its potential global use," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc.

Under the terms of the agreement, Horizon Pharma paid Boehringer Ingelheim EUR 5 million upon signing and will pay EUR 20 million upon closing for the rights for interferon gamma-1b in all territories outside of the United States, Canada and Japan. Horizon Pharma and Boehringer Ingelheim expect to close the transaction by year-end 2016, subject to the satisfaction of closing conditions.

Under the terms of a separate agreement with an undisclosed third party, Horizon Pharma also licensed the U.S., European and Canadian intellectual property rights for interferon gamma-1b for the treatment of Friedreich's ataxia. Interferon gamma-1b is currently not indicated or approved for the treatment of Friedreich's ataxia.

On May 5, 2016, the Company announced that it completed target enrollment of 90 patients in the Phase 3, randomized, double-blind, placebo controlled STEADFAST study evaluating ACTIMMUNE in patients with Friedreich's ataxia. Top-line results from the trial are expected by the end of 2016.

As a result of the agreement with Boehringer Ingelheim, Horizon Pharma will immediately begin investing in related manufacturing, supply chain, regulatory and commercial activities for interferon gamma-1b . As a result, the Company anticipates a reduction to 2016 adjusted EBITDA of approximately $10 million versus prior guidance.

About Horizon Pharma plc Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. Horizon Pharma markets nine medicines through its orphan, rheumatology and primary care business units. Horizon Pharma's global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com . Follow @HZNPplc on Twitter or view careers on our LinkedIn page.

Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements related to the anticipated consummation of the acquisition of the rights to interferon gamma-1b and the timing and benefits thereof, Horizon Pharma's strategy, plans, objectives, expectations (financial or otherwise) and intentions, the timing of results of the Phase 3 trial of ACTIMMUNE in Friedreich's ataxia, the potential for ACTIMMUNE as a treatment for Friedreich's ataxia and advanced solid tumors, future financial results and growth potential, anticipated product portfolio, development programs and other statements that are not historical facts. These forward-looking statements are based on Horizon's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to Horizon's ability to complete the transaction on the proposed terms and schedule; risks associated with acquisitions, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; risks related to future opportunities and plans for the acquired rights and related products; disruption from the proposed transaction, making it more difficult to conduct business as usual or maintain relationships with customers, employees or suppliers; the calculations of, and factors that may impact the calculations of, the acquisition price and the allocation of such acquisition price to the net assets acquired in accordance with applicable accounting rules and methodologies; the possibility that if the acquired rights do not create the perceived benefits of the proposed transaction as rapidly or to the extent anticipated by financial analysts or investors, the market price of the Horizon's shares could decline, risks of delays in completing the Phase 3 trial, risks associated with pre-clinical and clinical development of drug candidates, and risks that the actual effect of additional investments in interferon gamma-1b may differ from its expectations, as well as other risks related to Horizon's business detailed from time-to-time under the caption "Risk Factors" and elsewhere in Horizon Pharma's SEC filings and reports, including in its Annual Report on Form 10-K for the year ended December 31, 2015. Horizon Pharma undertakes no duty or obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or changes in its expectations.

Contacts: Investors: John Thomas Executive Vice President, Strategy and Investor Relations investor-relations@horizonpharma.com Tina Ventura Vice President, Investor Relations investor-relations@horizonpharma.com U.S. Media: Geoff Curtis Senior Vice President, Corporate Communications media@horizonpharma.com Ireland Media: Ray Gordon Gordon MRM ray@gordonmrm.ie

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duolingo Faces Class Action: Key Investor Steps

Updated Category News Views 75

Navigating Turbulent Times with Duolingo Holy moly, the dumpster fire that is the Duolingo (NASDAQ:DUOL) legal saga just got hotter. If you snagged yourself some shares between May 2, 2025, and February 26, 2026, you'd better sit down and grab some antacids—because the nauseating roller coaster is far from over. Robbins LLP is rounding up the troops for a class action,...

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 142

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
Dr. Kumar Joins Florida Cancer Specialists Team

Updated Category News Views 141

Welcoming a New Oncology Specialist to Bradenton What does a small but mighty addition mean for cancer care in Bradenton, Florida? Well, it feels like a big win for the locals. Dr. Vinod Kumar is the latest name to join the ranks of the Florida Cancer Specialists & Research Institute (FCS) at the Bradenton Cancer Center. With years under his belt in medical oncology and...

Continue Reading
SANY's Bold AI Showdown at bauma CHINA 2026

Updated Category News Views 27

SANY's Future Vision: AI Agents and Robotic Machinery The construction machinery game is about to get a whole lot smarter, if SANY has anything to say about it. They're rolling out their biggest show ever at bauma CHINA 2026, and the headline act? A fresh breed of AI agents and robotic machinery that promises to revolutionize the industry. Marking its 40-year legacy, SANY...

Continue Reading
Saint Luis Rey Launches Exclusive Palatinos Vitola

Updated Category News Views 89

New Beginnings for the Saint Luis Rey Brand You think you've seen it all in the cigar world, but then comes a debut like this that lights a fire under the lush tradition of Cuba. Enter Saint Luis Rey's new Palatinos vitola, a blend wrapped in the mystique of exclusivity for La Casa del Habano and Habanos Specialists. Whether you're a seasoned connoisseur or just dipping...

Continue Reading
iHeartMedia Faces 65% Drop: Fraud Investigation Launched

Updated Category News Views 62

Trouble Tunes for iHeartMedia Investors Alright folks, here's the skinny on iHeartMedia, Inc. These days, it's like everyone's out for a piece of iHeart, and not in the way you'd wanna see—unless you're SBS Law, those shareholder rights hotshots diving into another pond of legal ripples. Seems a heap of head-scratching's going down on their version of transparency with...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 301

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 128

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading
TCL Unveils Black Friday Steals on Smart Devices

Updated Category News Views 104

TCL's Big Move This Holiday Season When was the last time you saw a deal that actually made you stop and check your wallet? Well, TCL is giving you a reason to dig deep this Black Friday and Cyber Monday. They're slashing prices across smartphones and tablets, trying to elbow their way into your shopping cart with discounts up to $150. Now that's the kind of aggressive...

Continue Reading
Elite Robots Expands Global Reach with Mobile Manipulators

Updated Category News Views 112

Robots Hitting the Road? Picture this: robots that aren't just bolted to a factory floor but roam the production lines like tireless workers on wheels. That's what Elite Robots is betting on with their shiny new ELITEMISSION mobile manipulators. Not Just Any Old Robot These bad boys combine a robotic arm with an autonomous mobile platform. Think of an octopus getting off...

Continue Reading
d -->

Top 5 Most Recently Viewed Articles

Market Fluctuations: NVIDIA, Micron, and SMCI Stocks Overview

Updated Category News Views 192

Market Update for NVIDIA, Micron, and SMCI Stocks Shares of NVIDIA Corp. (NASDAQ: NVDA), Super Micro Computer, Inc. (NASDAQ: SMCI), and Micron Technology, Inc. (NASDAQ: MU) have recently taken a noticeable dip. This drop has caught the eye of both investors and market analysts, leading to questions about what might be driving this trend. Current Hurdles in the...

Continue Reading
Hyundai Motor Shines at Cannes with Grand Prix and Gold Lions

Updated Category News Views 250

Hyundai Motor's Exceptional Recognition at Cannes Lions Hyundai Motor Company has made a remarkable impact at the prestigious Cannes Lions International Festival of Creativity. The company has achieved a Grand Prix award for its short film, 'Night Fishing,' a project that has been praised for its inventive storytelling and creative prowess. This Grand Prix marks a...

Continue Reading
EWTN's Expansion in Stockholm: A Strategic Faith Move

Updated Category News Views 54

A Bold Move into Northern Europe In what's shaping up to be a calculated leap of faith, the EWTN Global Catholic Network opened a new office in Stockholm, Sweden. Now, I don't usually get all warm and fuzzy over religious broadcasts, but this is less about spreading sermons and more about tapping into a growing market. Yeah, you heard me right—market. With the Catholic...

Continue Reading
Investors Urged to Act Now Amid 143% Cash Flow Decline

Updated Category News Views 135

Significant Concerns for StubHub Investors Investors in StubHub Holdings, Inc. (NYSE: STUB) are being urged to pay close attention as serious allegations surface concerning the company's recent financial disclosures. The prominent investor rights law firm Hagens Berman is reaching out to those investors who acquired shares during the company's Initial Public Offering...

Continue Reading
Walmart Leverages Automation to Rival Amazon's Dominance

Updated Category News Views 200

Walmart Ignites Technological Transformation Walmart Inc (NYSE: WMT) is not just a retailer; it's transforming into a technology powerhouse. While many might think of Amazon.com Inc (NASDAQ: AMZN) as the leader in tech-driven logistics, Walmart is ramping up its efforts. Recently, during a call with investors, the company's CFO highlighted a key milestone: "More than 50%...

Continue Reading